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Abstract
Background: Interactions between spirometry and patient-reported outcomes in COPD are not well understood.
This systematic review and study-level analysis investigated the relationship between changes in FEV1 and changes
in health status with bronchodilator therapy.
Methods: Six databases (to October 2009) were searched to identify studies with long-acting bronchodilator
therapy reporting FEV1 and health status, dyspnoea or exacerbations. Mean and standard deviations of treatment
effects were extracted for each arm of each study. Relationships between changes in trough FEV1 and outcomes
were assessed using correlations and random-effects regression modelling. The primary outcome was St George’s
Respiratory Questionnaire (SGRQ) total score.
Results: Thirty-six studies (≥3 months) were included. Twenty-two studies (23,654 patients) with 49 treatment arms
each contributing one data point provided SGRQ data. Change in trough FEV1 and change in SGRQ total score
were negatively correlated (r = -0.46, p < 0.001); greater increases in FEV1 were associated with greater reductions
(improvements) in SGRQ. The correlation strengthened with increasing study duration from 3 to 12 months.
Regression modelling indicated that 100 mL increase in FEV1 (change at which patients are more likely to report
improvement) was associated with a statistically significant reduction in SGRQ of 2.5 (95% CI 1.9, 3.1), while a
clinically relevant SGRQ change (4.0) was associated with 160.6 (95% CI 129.0, 211.6) mL increase in FEV1. The
association between change in FEV1 and other patient-reported outcomes was generally weak.
Conclusions: Our analyses indicate, at a study level, that improvement in mean trough FEV1 is associated with
proportional improvements in health status.
Introduction
Chronic obstructive pulmonary disease (COPD) is a
complex, chronic condition, which is characterised by
progressive airflow limitation that is not fully reversible.
The major symptoms of COPD, such as dyspnoea,
cough and sputum production, are disabling and have
substantial impact on both patients’ health status and
the health care system [1,2]. Although treatment
involves several approaches, bronchodilator medications
are central to the management of COPD, improving
both lung function and symptoms [1].
The complex nature of COPD means that it is impor-
tant to assess treatment effectiveness in terms of
patient-reported outcomes, including symptoms or
health status scores [3]. Clinicians and policy makers
have recognised the importance of measuring health sta-
tus, in order to make informed patient management and
policy decisions [4], and clinician-led guidelines recom-
mend this approach for COPD [1,2]. However, regula-
tory authorities continue to emphasise airflow
obstruction, measured by spirometry, as the primary
outcome required for registration trials of new
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bronchodilators. It is therefore relevant to establish if
and how changes in lung function may translate into
patient-reported outcomes.
Although primary studies with bronchodilators fre-
quently report both spirometry and patient-reported
outcomes, the relationships between outcome measures
are poorly understood. A study by Stahl et al. published
in 2001, showed weak correlations between the St
George’s Respiratory Questionnaire (SGRQ) and cough,
breathlessness, forced expiratory volume in 1 second
(FEV1) and walking distance but reported only limited
supporting patient level data [5]. Study-level meta-analy-
sis is a meaningful and cost-effective approach to
addressing a clinical research question, particularly
where individual patient data is difficult to obtain [6].
We are unaware of any study level analysis which has
specifically addressed how lung function is related to
outcomes.
The present study was a systematic review of rando-
mised controlled trials (RCTs) of inhaled bronchodila-
tors in adult patients with stable COPD, which reported
change in trough FEV1, the primary physiological out-
come in most studies of long-acting bronchodilators,
alongside patient-reported outcomes. The primary
objective was to assess at a study level the relationship
between FEV1 change and health status change, as mea-
sured by the SGRQ, and to estimate the increase in
mean FEV1 associated with a clinically important
improvement in health status. As secondary objectives,
we assessed the relationship between change in FEV1
and SGRQ domains, the influence of study duration,
and the relationship between change in FEV1 and
change in other patient-reported outcomes, such as dys-
pnoea, as measured by the Transition Dyspnea Index
(TDI), and COPD exacerbations.
Methods
Search strategy
We sought all relevant trials regardless of language or
publication status (published, unpublished, in press, and
in progress). The following databases were searched:
MEDLINE (1980 to March 2009); EMBASE (1980 to
March 2009); “Cochrane Reviews” (CDSR, Cochrane
Library issue 4 2009); “Clinical Trials” (CENTRAL,
Cochrane Library issue 4 2009); DARE (March 2009,
CRD website); and HTA (March 2009, CRD website).
Search strategies with keywords were developed specifi-
cally for each database: the search strategy for MED-
LINE is provided in Additional file 1. In addition,
databases of completed and ongoing trials such as Clini-
calTrials.gov, websites of licensing agencies, the Guide-
lines International Network and worldwide HTA were
searched and references in retrieved articles and sys-
tematic reviews were checked.
Selection criteria
Our selection criteria included published and unpub-
lished, parallel, RCTs of ≥12 weeks duration. Non-RCTs
were excluded, given that RCTs represent the most
robust level of efficacy evidence, especially for outcomes
reported by patients. Studies had to include COPD
patients (according to any definition) aged ≥35 years
with stable disease (no exacerbations for at least 4
weeks prior to study entry or ‘stable COPD’ as an inclu-
sion criteria), chronic bronchitis (excluding acute/spastic
bronchitis), or emphysema. Trials which recruited
mixed populations (e.g. asthma and COPD) were
excluded, unless separate data were reported for COPD
patients.
We included all studies that had intervention treat-
ment arms using a long-acting inhaled bronchodilator
treatment as monotherapy for stable COPD, e.g. long-
acting b2-agonists (LABA), long-acting muscarinic
antagonists (LAMA), LABA + LAMA combinations,
methylxanthines and placebo, thus limiting the analysis
to drugs with similar pharmacodynamic properties. The
comparator treatment could include a placebo or any of
the interventions listed above. Short-acting treatment
arms were excluded. Studies had to report change in
trough FEV1 from baseline and at least one patient-
reported outcome (health status [SGRQ], exacerbations
or dyspnoea [TDI]). Trough FEV1 was extracted as
reported in the primary studies. Although there was
some variation in details provided, this was usually
defined as the measurement of FEV1 taken before the
first morning dose. Both the SGRQ and TDI are disease
specific questionnaires. The SGRQ consists of three
domains (Symptoms, Activity and Impacts) and a Total
score which provides values between 0 and 100. Higher
values correspond to greater impairment, with a 4 unit
change in total score considered to be the minimal clini-
cally important difference (MCID) [7]. The TDI repre-
sents a change from baseline and provides values
between -9 and 9 with positive values indicating
improvement and a 1 unit change representing the
MCID [8].
Trial selection, data extraction and quality assessment
Two reviewers (MW and GW) independently inspected
the abstract of each reference identified to determine
potential relevance. For potentially relevant articles, or
in cases of disagreement, the full article was obtained,
independently inspected, and inclusion criteria applied.
Any disagreement was resolved through discussion and
checked by a third reviewer. Data for each study were
extracted by one reviewer and checked for accuracy by a
second reviewer, using a standardised data extraction
sheet. Any disagreements were resolved by consensus.
Baseline and endpoint data were extracted where
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available, otherwise, change from baseline data were
extracted. Outcome data were extracted for all available
time points. If studies did not report numerical data,
values were estimated from graphs, and standard devia-
tions were imputed using weighted averages from other
studies which included the same drug comparison and
time point, in line with recommended methodology [9].
Quality assessment was carried out by one reviewer,
using the Cochrane Collaboration quality assessment
checklist, and checked for accuracy by a second
reviewer. Any disagreements were resolved by consen-
sus. Results are summarised in Additional file 2.
Data analysis
The relationship between mean changes in FEV1 and
mean changes in SGRQ scores for each treatment arm
from each study was assessed visually using scatter
plots. Plots were constructed for SGRQ total score and
SGRQ domains (Symptoms, Activity and Impacts) at
any time point measured; where studies reported multi-
ple time points, only data for the 6 month time point
(the most frequently measured time point across stu-
dies) were used for analyses that include all time points.
For the relationship between changes in FEV1 and
SGRQ total score, separate plots were constructed for
the 3, 6 and 12 month time points. Pearson correlation
coefficients were calculated and regression lines from a
simple linear regression model were added to each plot.
These were used to estimate the mean change in FEV1
corresponding to 3- and 4-unit changes in SGRQ, and
the mean change in SGRQ score associated with a 100
mL increase in FEV1 (magnitude of change in FEV1 at
which patients are more likely to report improvement in
an important clinical parameter such as health status)
[10].
Random effects regression modelling was used to
explore the effects of the change in FEV1 on the change
in total SGRQ score. The model included time (3, 6 or
12 months) as a categorical variable and study was trea-
ted as a random effect to allow for correlation within
each study, thus adjusting for possible confounders.
This model allows an estimate of the strength of the
relationship between FEV1 and SGRQ (the size and sta-
tistical significance of the model coefficient). Where suf-
ficient data were available, similar methods were applied
to investigate the relationship between changes in FEV1
and the outcomes TDI and percentage of patients
experiencing at least one COPD exacerbation. All statis-
tical analyses were performed in Stata 10.1.
Results
Overview of included studies
The search strategy initially yielded 9676 references.
Figure 1 illustrates the flow of studies through the review
process. After screening for potential relevance, 175 full
papers were assessed for possible inclusion. From these,
36 studies met the inclusion criteria [5,11-45]. A further
two references were identified to be duplicates of pre-
viously identified studies [46,47]. Twenty-two studies
with 49 treatment arms contributed to the primary ana-
lyses exploring the relationship between changes in FEV1
and SGRQ scores [5,11-31]. Twenty nine studies pro-
vided data on exacerbations [11-13,16-22,25,26,29-45]
and eight studies provided data on dyspnoea
[11-13,21,26,30,33,41]. All studies were parallel, RCTs of
LAMA (tiotropium) and/or LABA (salmeterol, formo-
terol, arformoterol) with or without a placebo arm.
Table 1 shows the study characteristics for studies
providing data on FEV1 and SGRQ scores, exacerba-
tions, or dyspnoea. The 49 data sets for the SGRQ ana-
lyses included 23,654 patients, of whom 72% were male
with an average age of 64 years, and mean baseline
FEV1 43% predicted.
FEV1 change and change in SGRQ total score
Using all treatment arms and all time points (n = 49),
Figure 2 shows a moderate negative correlation between
the mean change in trough FEV1 and change in SGRQ
total score; greater increases in FEV1 were associated
with greater reductions (i.e. improvements) in SGRQ.
Zero change in FEV1 was associated with a significant
reduction in SGRQ score of 2.5 (95% CI 1.8, 3.3). The
additional reduction in SGRQ associated with a 100 mL
increase in FEV1 was 1.6 (0.7, 2.5), making the total
improvement in SGRQ 4.1 units. When excluding pla-
cebo arms, zero change in FEV1 was associated with a
reduction in SGRQ total score of 4.1 (2.7, 5.6). However
the association between change in FEV1 and additional
change in SGRQ total score was no longer statistically
significant; for a 100 mL increase in FEV1 the reduction
in SGRQ was 0.4 (-1.1, 1.9).
Table 2 illustrates the increasing probability of reach-
ing a clinically meaningful improvement in SGRQ with
increasing levels of FEV1 improvement. For treatment
arms where mean changes in FEV1 were ≥100 mL
(using the largest ΔSGRQ values for studies with data
for multiple time points) the probability of reaching a
mean reduction in total SGRQ score of 4 units was 80%.
Random effects modelling found that a 100 mL
increase in FEV1 was associated with an estimated
reduction in SGRQ total score of 2.5 (1.9, 3.1). This
equates to a clinically meaningful reduction of 4 units in
SGRQ being associated with an estimated improvement
in FEV1 of 160.6 (129.0, 211.6) mL. When this analysis
was repeated excluding the placebo arms, a 100 mL
increase in FEV1 led to an estimated change in SGRQ
score of 1.02 (0.0, 2.5) although the association between
FEV1 and SGRQ score was no longer significant.
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FEV1 change and SGRQ by study duration and SGRQ
domains
As shown in Table 3, when data were analysed by time,
change in trough FEV1 and change in SGRQ total score
remained negatively correlated and the strength of the
correlation increased with time for 3 (n = 16), 6 (n =
20) and 12 (n = 19) month time points. Reductions in
SGRQ associated with zero change in FEV1 were 1.6
(95% CI -0.4, 3.6), 2.2 (1.1, 3.3) and 2.6 (1.8, 3.4), at 3, 6
and 12 months, respectively. Further reductions in
SGRQ score associated with a 100 mL increase in FEV1
were 1.6 (-0.2, 3.5), 2.1 (1.3, 2.9) and 2.7 (1.5, 4.0) at 3,
6 and 12 months respectively.
When data for all treatment and placebo arms, regard-
less of time, were stratified by SGRQ domains, there was
a weak, non-significant negative correlation between
change in trough FEV1 and change in SGRQ Symptoms
score (Table 3). However there was a weak, but statisti-
cally significant negative correlation with change in
SGRQ Activity score and a moderate and statistically
significant negative correlation with change in SGRQ
Impacts score.
FEV1 change and other patient-reported outcomes
Table 4 presents the results for the relationship between
change in FEV1, and TDI and exacerbations. Consider-
ing all treatment arms and 3, 6 and 12-month time
points (n = 15), there was a moderate positive correla-
tion between change in TDI and change in FEV1. The
improvement in TDI associated with a 100 mL increase
in FEV1 was 0.5 although this was below the 1 unit
MCID for TDI [8]. When placebo arms were excluded
from the analysis there was no evidence of an associa-
tion between change in FEV1 and change in TDI score.
Increasing FEV1 was associated with a reduction in
the proportion of patients experiencing at least one
exacerbation, although the correlation was weak (Table
4). An increase of 100 mL in trough FEV1 was asso-
ciated with an estimated 6.0% reduction in the propor-
tion of patients experiencing at least one exacerbation.
Figure 1 Flow of studies through the review process. Abbreviations: MEDLINE, medical literature analysis and retrieval system online;
EMBASE, Excerpta Medica database; CRD, Centre for Reviews and Dissemination; DARE, Database of Abstracts of Reviews of Effects; HTA, Health
Technology Assessment; GIN, Guidelines International Network.
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Table 1 Description of studies providing data on FEV1 and SGRQ, dyspnoea (TDI), or exacerbations for long-acting
bronchodilators
Study Duration,
(months)*
Number
randomised (by
treatment)
Age,
(years)
Male,
(%)
Smoking
history,
(pack years)
FEV1 %
predicted
Outcomes reported
SGRQ
total
SGRQ
domains
Number with ≥
1 exacerbation
TDI
Aaron 2007 [11] 12 304 (T 156, T + S 148) 65.9 (8.6) 56 50.3 (27.6) 41.7 (13.3) Yes No Yes Yes
Baumgartner 2007
[12]
3 428 (A 141, S 144, Pl
143)
62.9 (9.0) 58 NR 40.8 (12.7) Yes Yes Yes Yes
Beeh 2006 [32] 3 1639 (T 1236, Pl 403) 62.2 (8.7) 76 35.8 (19.5) 45.5 (14.9) No No Yes No
Boyd 1997 [33] 4 456 (S 229, Pl 227) 61.5 79 NR NR No No Yes Yes
Briggs 2005 [34] 3 653 (T 328, S 325) 64.4 (6.3) 67 55.9 (28.8) 37.7 (12.1) No No Yes No
Brusasco 2003 [13] 6 1207 (T 402, S 405, Pl
400)
64.2 (8.4) 76 43.8 (23.2) 38.5 (11.8) Yes No Yes Yes
Calverley 2003
[14]
12 733 (S 372, Pl 361) 63.3 (8.6) 72 43.6 (22.2) 44.3 (13.8) Yes No No No
Calverley 2007
[15]
12 6184 (S 1521, Pl 1524) 65.0 (8.2) 76 49.0 (27.3) 43.9 (12.5) Yes No No No
Campbell 2005
[16]
6 442 (F 225, Pl 217) 60 68 37 53.8 Yes No Yes No
Casaburi 2000 [35] 3 470 (T 279, Pl 191) 65.2 (8.8) 65 62.9 (32.0) 39.0 (13.9) No No Yes No
Casaburi 2002 [17] 12 921 (T 550, Pl 371) 65.0 (9.0) 65 61.0 (30.5) 38.6 (13.9) Yes Yes Yes No
Chan 2007[18] 12 913 (T 608, Pl 305) 66.8 (8.8) 60 50.4 (23.9) 39.4 (13.5) Yes Yes Yes No
Chapman 2002
[19]
6 408 (S 201, Pl 207) NR 64 38 45 Yes Yes Yes No
Covelli 2005 [36] 3 196 (T 100, Pl 96) 64.6 (9.0) 58 65.5 (33.4) 39.4 (13.4) No No Yes No
Dahl 2001 [20] 6 392 (F 192, Pl 200) 63.5 (8.4) 77 41.8 45.0 (12.7) Yes Yes Yes No
Donohue 2002
[21]
6 623 (T 209, S 213, Pl
201)
64.9 (7.9) 75 47.0 (25.0) 42.3 (9.3) Yes Yes Yes Yes
Donohue 2008
[37]
12 793 (Af 528, S 265) 64.2 (8.8) 59 NR 38.0 (13.1) No No Yes No
Dusser 2006 [38] 12 1010 (T 500, Pl 510) 64.8 (9.3) 88 NR 47.9 (12.7) No No Yes No
Freeman 2007 [39] 3 395 (T 200, Pl 195) 64.9 (9.1) 54 37.4 (17.3) 48.9 (10.6) No No Yes No
Gross 2008 [22] 3 351 (F 123, Pl 114) 62.7 (8.9) 58 NR 44.5 (12.1) Yes Yes Yes No
Johansson 2008
[40]
3 224 (T 107, Pl 117) 61.5 (8.3) 48 31.5 (12.1) 73.4 (12.6) No No Yes No
Jones 1997 [23] 3 189 (S 94, Pl 95) 62.5 (8.0) 79 NR 46.0 (15.0) Yes No No No
Mahler 1999 [41] 3 411 (S 135, I 133, Pl
143)
63.5 (8.5) 74 60.2 (32.5) 40.0 No No Yes Yes
Moita 2008 [42] 3 311 (T 147, Pl 164) 64.3 (8.6) 95 55.0 (23.6) 41.4 (14.1) No No Yes No
Niewoehner 2005
[43]
6 1829 (T 914, Pl 915) 67.9 (8.6) 99 68.4 (36.0) 35.6 (12.6) No No Yes No
Rennard 2009 [24] 12 976 (F 495, Pl 481) 63.0 (9.1) 65 NR 40.1 (11.7) Yes Yes No No
Rossi 2002 [25] 12 645 (F 214, Pl 220) 62.7 83 NR 47.7 Yes Yes Yes No
Sepracor inc.
NCT00250679
2009 [26]
6 296 (F 147, Af 149) 64.7 (8.4) 61 NR 41.0 (12.6) Yes No Yes Yes
Stahl 2001 [5] 3 121 (F 61, Pl 60) 64 52 NR 33.3 Yes No No No
Stockley 2006 [27] 12 726 (S 316, Pl 318) 62.4 (9.2) 67 39.7 (21.6) 46.0 (14.3) Yes Yes No No
Tashkin 2008 [28] 6 584 (F 284, Pl 300) 63.4 (9.6) 67 NR 40.4 (12.5) Yes Yes No No
Tashkin 2008 [29] 12 5993 (T 2987, Pl 3006) 64.5 (8.5) 75 48.7 (28.0) 39.4 (12.0) Yes No Yes No
Tashkin 2009 [30] 3 255 (T + F 124, T 131) 63.8 (8.6) 66 NR NR Yes Yes Yes Yes
Tonnel 2008 [31] 9 554 (T 266, Pl 288) 64.2 (9.9) 86 43.7 (21.9) 46.8 (12.8) Yes Yes Yes No
van Noord 2000
[44]
3 97 (S 47, Pl 50) 74.0 (6.5) 88 NR 40.3 (10.7) No No Yes No
Vogelmeier 2008
[45]
6 847 (F 210, T 221, F +
T 207, Pl 209)
62.6 (8.8) 78 38.0 (19.7) 51.2 (9.9) No No Yes No
Data are mean (SD) unless otherwise stated. *time point used in analyses
Af: arformoterol, F: formoterol, FEV1: forced expiratory volume in one second, NR: not reported, Pl: placebo, S: salmeterol, SGRQ: St George’s Respiratory
Questionnaire, T: tiotropium, TDI: Transition Dyspnea Index
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When placebo arms were excluded from the analysis (n
= 33), the correlation was similar (r = -0.35; p = 0.046);
zero change in FEV1 corresponded to an estimated
31.3% (95% CI 21.3, 41.3) of patients experiencing at
least one exacerbation and a 100 mL increase in FEV1
was associated with an estimated 10.2% (0.2, 20.2)
reduction in the numbers of patients experiencing an
exacerbation.
Discussion
Our study-level analysis demonstrated a relationship
between improved lung function (as measured by FEV1)
and improvements in health status (as measured by
SGRQ) in adult patients with stable COPD who are
treated with long-acting inhaled bronchodilators. Results
of random-effects regression modelling indicated that a
100 mL increase in FEV1 was associated with a reduc-
tion in SGRQ total score of 2.5 units. This equates to a
clinically meaningful reduction of 4 units in SGRQ
being associated with an estimated improvement in
FEV1 of 160.6 mL. These results were supported by cor-
relation analyses which demonstrated a moderate nega-
tive correlation between change in total SGRQ score
and change in trough FEV1, when all treatment arms
were considered. When the placebo arms were excluded
from the analyses the relationship was not significant,
which may be due in part to the reduction in sample
size, but principally because clustering of results for the
placebo arms around zero for change in FEV1 and
change in SGRQ increased the scatter in the data which
allowed correlations to emerge. It should be emphasised
that the principal objective of our review was to investi-
gate the relationship between trough FEV1 and out-
comes rather than test differential effects of treatment,
so all use of treatment arms including placebo arms was
appropriate. It is important to note that our analysis
focussed on studies including long-acting
Figure 2 Scatter plot of mean change in FEV1, for all
treatments (LAMA, LABA, LAMA+LABA) and placebo versus
change in SGRQ total score at a study level for all study
period.
Table 2 Study level probability of reaching a clinically
meaningful reduction in SGRQ total score according to
the magnitude of improvement in FEV1
Improvement in FEV1 (mL) Number of study arms achieving
SGRQ reduction, n/N (%)
4 units 3 units
≥40 17/35 (49) 21/35 (60)
≥60 14/25 (56) 18/25 (72)
≥80 12/17 (71) 14/17 (82)
≥100 12/15 (80) 14/15 (93)
≥120 8/10 (80) 9/10 (90)
FEV1: forced expiratory volume in 1 second, SGRQ: St George’s Respiratory
Questionnaire
Table 3 Correlations for mean change in FEV1 for all
treatments (LAMA, LABA, LAMA + LABA) and placebo
versus reduction in SGRQ scores at a study level, by
study period and SGRQ domain
SGRQ Study period Data points, n Correlation, r* p value
Total score All 49 -0.46 <0.001
3 months 16 -0.44 0.08
6 months 20 -0.61 0.004
12 months 19 -0.74 <0.001
Symptoms All 27 -0.34 0.08
Activity All 27 -0.38 0.049
Impact All 30 -0.50 0.004
*Pearson correlation coefficient
FEV1: forced expiratory volume in 1 second, LAMA: long-acting muscarinic
antagonists, LABA: long-acting b2-agonists, SGRQ: St George’s Respiratory
Questionnaire
Table 4 Relationships between mean change in FEV1 and
the outcomes Transition Dyspnea Index (TDI) and
percentage of patients experiencing at least one
exacerbation for all treatments (LAMA, LABA, LAMA +
LABA) and placebo: correlation coefficients and model
outputs
Outcome
TDI
total
score
Percent of patients
experiencing at least one
exacerbation
Data points (n) 15 50
Correlation between change in
outcome and change in FEV1
(r*)
0.56 -0.27
p value 0.02 0.049
Outcome change for 0 mL
change in FEV1 (95% CI)**
0.7
(0.3,
1.2)
26.7 (21.7, 31.3)%
Additional change in outcome
for 100 mL change in FEV1
(95% CI)**
0.5
(0.1,
0.9)
-6.0 (-0.04,-11.9)%
*Pearson correlation coefficient; **output from random effects regression
modelling
FEV1: forced expiratory volume in 1 second, LAMA: long-acting muscarinic
antagonists, LABA: long-acting b2-agonists
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bronchodilators. Relationships between FEV1 and out-
comes may be different for anti-inflammatory treat-
ments. Further, different results may have been obtained
had we assessed the relationship between peak FEV1
and outcomes. However, we selected the trough mea-
surement since it was the primary endpoint and there-
fore best documented outcome in most studies.
Despite the discrepancy in outcome measures required
to demonstrate clinical effectiveness between the regula-
tory authorities and reimbursement agencies, such as
the National Institute for Health and Clinical Excellence
in the UK and the Institute for Quality and Efficiency in
Health Care in Germany, few studies have investigated
the relationship between change in lung function and
change in patient-reported outcomes. We are aware of
no other analysis addressing this issue at a study level.
However, our data are consistent with the results of
patient-level analyses [5,48], although in these studies
the strength of the relationship between change in
SGRQ and FEV1 was too weak to allow health status
gains to be inferred from spirometric changes [48]. This
is not a limitation, but rather reflects how different indi-
viduals with the same physiological limitations may
experience differing effects on their health status.
Our study indicated that the correlation between
change in trough FEV1 and change in SGRQ total score
appears to strengthen with increasing study duration
from 3 to 6 to 12 months. Over an intermediate and
longer term period, the impact of an improvement in
lung function may have a greater effect on patient well-
being, although in our analysis, the limited data reported
in the included studies did not allow us to assess
whether changes in FEV1 at 3 months correlated with
longer term changes in outcomes. There was also a
trend to increasing mean change in SGRQ, across all
study arms, with longer study duration. When data were
analysed by SGRQ domain, the association between
change in FEV1 and change in SGRQ scores was still
present for the Activity and Impacts domains. A weak
correlation between SGRQ Symptoms domain and FEV1
has been reported ever since the first validation of this
instrument [3].
Another important issue to be addressed is the “mean-
ing” of the 100 mL increase in FEV1 associated with a
reduction in SGRQ total score of 2.5 units, and an esti-
mated improvement in FEV1 of 160 mL in relation to a
clinically meaningful reduction of 4 units in SGRQ. There
is no universally accepted approach for determining the
clinical important difference of a measurement. As a mea-
sure, SGRQ reflects aspects of COPD beyond lung func-
tion alone [48]. In our analysis, the corresponding increase
in health status in treatment arms with larger improve-
ment in FEV1 enhances the ability to interpret lung func-
tion changes at a study level, but not at a patient level.
Depending on the intervention under study, FEV1 may
offer the perspective of an intermediate end point in asses-
sing likely treatment effectiveness. However, treatment
effectiveness cannot be based exclusively on spirometry,
requiring assessment of other relevant clinical parameters
such as patient-reported health status.
It is interesting to note that a zero change in FEV1
still resulted in a reduction in SGRQ score of 2.5. This
effect has been noted in many clinical trials in COPD
and appears to relate to a ‘Hawthorne effect’, whereby
patients receive better care by participating in the trial
[49]. It could relate to a number of different factors,
including improved compliance with treatments which
may not all have bronchodilator effects.
There was also some evidence of a positive relation-
ship between change in FEV1 and other outcomes, i.e.,
improvements in TDI score and reduction in the pro-
portion of patients experiencing at least one exacerba-
tion. These associations were weaker than those
observed with SGRQ. However, correlation data for TDI
versus trough FEV1 were limited by the relatively small
number of studies (n = 8) reporting both outcome mea-
sures. For data on exacerbations, longer study durations
would have been required to fully assess the apparent
negative correlation with change in FEV1.
Our review has limitations. We did not explicitly seek
primary studies assessing the correlation between out-
come measures and the restriction of our search strategy
to RCTs in order to enhance the quality of the analysis
means that observational studies of this type would not
have been identified. In addition, the objectives of
included studies differed from those of the review:
included studies were generally designed to measure the
effects of treatment upon COPD outcomes, whereas we
were interested in the relationships between outcome
measures. Included studies tended to present full results
for their primary outcome measure only, with reporting
of additional outcomes being poor and measures of var-
iance were often absent. Thus, standard deviations had
to be imputed for a high proportion of the data sets
included in our analyses. In addition, many studies did
not report numerical data and values were estimated
from graphs, although such approaches are consistent
with established systematic review methodology.
Although our review did not address treatment effect
sizes, our objectives did include an assessment of the
relationships between treatment effects upon treatment
effect sizes (data addressing this objective were sparse
and not included in this article). For this reason only
RCTs of long acting bronchodilators which included a
placebo arm or which compared different classes of
bronchodilator were compared.
Finally, the correlation analyses used to assess the rela-
tionships between patient-reported outcomes and FEV1
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where data were insufficient to support regression model-
ling, combined treatment arms from different studies.
Thus the data were essentially treated as observational
cohorts and the strengths of the RCT design were lost.
Combining the data in this way does not take account of
differences between studies, such as treatment and dose,
and participant baseline characteristics, which may affect
estimates of correlation. In theory, this limitation can be
overcome using random effects regression modelling.
However, even where such modelling was possible, the
number of explanatory variables which could be included
was constrained by both the reporting of these variables in
the primary studies and the size of the data set; both poor
reporting and small data sets were factors in this review.
The results of this review give important new insight
into the relationship between FEV1, a key primary out-
come required by regulatory authorities for COPD clini-
cal trials, and patient-reported outcomes such as health
status, dyspnoea and exacerbations, which are of greater
interest to clinicians, patients and reimbursement agen-
cies. Our analyses have been limited by the size and
quality of the available data set and are encouraging, but
should be considered hypothesis generating and warrant
further investigation.
This study-level analysis indicated that improvement
in trough FEV1 with inhaled bronchodilators may be
associated with improvement in health status and may
also be associated with improvements in other patient-
reported outcomes. Although the strength of the asso-
ciation was modest, improvements in both FEV1 and
SGRQ, relative to changes likely to be clinically relevant,
were of similar magnitude. FEV1 may offer the perspec-
tive of an intermediate endpoint in assessing treatment
effectiveness at a study level.
Additional material
Additional file 1: Search strategy for the MEDLINE database.
Additional file 2: Quality assessment of studies selected for
inclusion in the systematic review.
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